Glibenclamide Therapy in Diabetes Mellitus
S.K. Bhatia, D. R. Hadden, D. A. D. Montgomery, Janelle Weaver
Abstract
Open-access reader
S.K. Bhatia, D. R. Hadden, D. A. D. Montgomery, Janelle Weaver
Abstract
Open-access reader
In an initial trial of glibenclamide in the treatment of maturity onset diabetes mellitus 28 patients were treated for up to one year and no toxic effects or side-effects were encountered. The hypoglycaemic potency of this drug is such that 5 mg. of glibenclamide corresponds to about 1,500 mg. of tolbutamide and 375 mg. of chlorpropamide.
OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In an initial trial of glibenclamide in the treatment of maturity onset diabetes mellitus 28 patients were treated for up to one year and no toxic effects or side-effects were encountered. The hypoglycaemic potency of this drug is such that 5 mg. of glibenclamide corresponds to about 1,500 mg. of tolbutamide and 375 mg. of chlorpropamide.
Key concepts: Glibenclamide, Chlorpropamide, Tolbutamide, Diabetes mellitus, Medicine, Potency, Internal medicine, Drug